| Brian Michael Goodman, MD | |
|
1 Medical Park, Wheeling, WV 26003-6379 | |
| (304) 243-8375 | |
| Not Available |
| Full Name | Brian Michael Goodman |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 21 Years |
| Location | 1 Medical Park, Wheeling, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740453893 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home Health Services Of Self Regional Healthcare | Greenwood, SC | Home health agency |
| Self Regional Healthcare | Greenwood, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Self Medical Group | 6002953916 | 281 |
News Archive
A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD).
In recognition of World AIDS Day on Dec. 1, Department of Health Secretary Everette James today reminded Pennsylvanians to be tested regularly for HIV - the virus that causes AIDS.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
UT Southwestern Medical Center researchers have genetically engineered a laboratory mouse in which pancreatic beta cells can regenerate after being induced to die. The new animal model's regenerative ability may provide future insights into improved treatments of diabetes, which affects millions of Americans.
› Verified 8 days ago
| Entity Name | Self Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982836847 PECOS PAC ID: 6002953916 Enrollment ID: O20091027000071 |
News Archive
A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD).
In recognition of World AIDS Day on Dec. 1, Department of Health Secretary Everette James today reminded Pennsylvanians to be tested regularly for HIV - the virus that causes AIDS.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
UT Southwestern Medical Center researchers have genetically engineered a laboratory mouse in which pancreatic beta cells can regenerate after being induced to die. The new animal model's regenerative ability may provide future insights into improved treatments of diabetes, which affects millions of Americans.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian Michael Goodman, MD 629 Main St, Wheeling, WV 26003-2525 Ph: () - | Brian Michael Goodman, MD 1 Medical Park, Wheeling, WV 26003-6379 Ph: (304) 243-8375 |
News Archive
A small, retrospective study determined that percutaneous coronary intervention (PCI) was safe in patients with significant coronary artery disease (CAD) who were referred for liver transplantation. Larger studies are needed to determine the effectiveness of angioplasty in patients with end-stage liver disease (ESLD).
In recognition of World AIDS Day on Dec. 1, Department of Health Secretary Everette James today reminded Pennsylvanians to be tested regularly for HIV - the virus that causes AIDS.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
UT Southwestern Medical Center researchers have genetically engineered a laboratory mouse in which pancreatic beta cells can regenerate after being induced to die. The new animal model's regenerative ability may provide future insights into improved treatments of diabetes, which affects millions of Americans.
› Verified 8 days ago
David M Haybron, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 10 Medical Park, Suite 101, Wheeling, WV 26003 Phone: 304-243-3889 Fax: 304-243-8802 | |
Dr. Rosemarie Elizabeth Hardin, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park, Suite 704, Wheeling, WV 26003 Phone: 304-243-6530 |